Share these talks and lectures with your colleagues
Invite colleaguesWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login
or review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- COPD case study: patient KM
- COPD case study: KM history
- PFTs
- Chest CT
- Combined assessment of COPD
- Therapeutic options: COPD medications
- Pharmacologic therapy (1)
- KM’s past and current treatment
- Pharmacologic options (1)
- Suitability of proposed treatment strategies
- Managing KM’s progressive COPD
- Changing delivery devices
- Factors to consider when selecting delivery devices
- Changes in FEV1 at 2 hr
- Fluticasone vs. Budesonide
- ICS and risk of pneumonia for COPD
- Fluticasone vs. Budesonide: dosage
- KM follow up
- Pharmacologic options (2)
- Dual bronchodilators: LAMA/LABA
- Trial of roflumilast
- Efficacy of roflumilast in the COPD
- Roflumilast: patients with severe COPD
- Pharmacologic options (3)
- Trial of N-acetylcysteine (NAC)
- Trial of NAC
- Daily Rx with azithromycin
- COPD study participants
- Concerns with drugs
- Prophylactic antibiotic trials
- Azithromycin/Placebo hazard ratios
- Responses to daily azithromycin therapy
- Pharmacologic therapy (2)
- Theophylline
- Non-pharmacologic management
Topics Covered
- COPD case study
- Combined assessment of COPD
- Therapeutic options: COPD medications
- Advantages, limitations, and concerns about available therapy for COPD
- Combination therapies
- Risk factors for progression, COPD exacerbations, and complications with current therapy
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Chatila, W. (2016, February 29). Tailoring care for advanced COPD [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved January 22, 2021, from https://hstalks.com/bs/3234/.Publication History
Financial Disclosures
- Dr. Wissam Chatila has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Tailoring care for advanced COPD
Published on February 29, 2016
48 min
Other Talks in the Series: Advances in Chronic Obstructive Pulmonary Disease (COPD)
Transcript
0:00
I'm presenting a COPD case study.
My name is Wissam Chatila.
0:06
KM is a 58-year-old man,
diagnosed with emphysema in 2010.
He presents to my clinic
for a second opinion
for management of his COPD.
He has no significant
past medical history.
He has no prior history of
cardiovascular disease or metabolic
diseases.
He is a retired airport
technician and former smoker.
He quit one year ago, and no
other history of illicit drug
use and/or prior exposures.
His family history is
significant, with a brother
who has a history of asthma.
0:45
He had three exacerbations per year
over the last two or three years,
some requiring hospitalizations.
He had two pneumonias
over the last two years,
in addition to his exacerbations.
He has no wheezing,
by history, but has
a slight cough, minimally
productive, with
occasional clear mucus production.
His mMRC score is 3.
That is, he is breathless with
mild to moderate activity.
He stops for breath
after walking 100 yards
or after a few minutes
on level ground.
He gets substantial
relief with the use
of albuterol nebulizer
treatments that he
takes three or four times per day.
1:34
This slide shows his
pulmonary function test.
The first one were done in May,
2012, by his pulmonologist.
His vital capacity was 105,
FEV1, 33%, and is FEB1/FVC ratio
is 25%, significant for a
very severe obstruction.
Air trapping, his TLC is 128, and
RV is 209, so he's significantly
hyperinflated and air trapped.
The most recent
pulmonary function test
shows a significant deterioration
in his air flow obstruction,
with an FEV1 of 17%,
compared to the 33%,
so it continues to be very severe
and much worse compared to 2012.
His hyperinflation and air
trapping also have progressed,
with a TLC of 138%, and RV, 295%.
His DLCO is also
severely reduced to 22%,
and on the six-minute walk
distance, he walked 165 meters,
his lowest oxygen
saturation was 80%,
and he required 6 liters
per minute to maintain
an oxygen saturation about 90%.
His arterial blood gas does not
show significant hypercapnia,
but he was hypoxemic
with a PO2 of 65.